Skin care essence and preparation method thereof

Abstract

The invention provides a skin care essence and a preparation method thereof. The skin care essence is prepared by compounding 80-120 mL of a nano emulsification system containing alpha-bisabolol and 4-6 mL of a liposome dispersion liquid containing rapamycin. The rapamycin in the skin care essence is subjected to liposome encapsulation treatment to improve the stability and the skin permeability, the alpha-bisabolol is dissolved in the lipophilic oil phase to play anti-inflammatory and soothing roles, the two fat-soluble active components are synergistically dispersed through the nano-emulsification process, and the skin care essence has the effects of diminishing inflammation and soothing skin. Under the condition of low irritation, triple effects of anti-inflammation, anti-aging and barrier repair are achieved, and the skin care product has good stability and skin compatibility and is suitable for long-term care of sensitive skin and the like.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and more specifically, to a skin care essence and its preparation method. Background Technology

[0002] As people age and are affected by external environmental factors, skin aging issues such as wrinkles and sagging have gradually gained widespread attention, leading to the continuous development of related skincare products. Current serums typically contain active ingredients such as Vitamin C, hyaluronic acid, peptides, antioxidants, and plant extracts, aiming to penetrate deep into the skin to address signs of aging such as dryness, dullness, fine lines, and sagging, while simultaneously enhancing the skin's self-repair and protective abilities.

[0003] For example, Chinese patent application number 202510217480.5 discloses an essence with repairing and moisturizing functions and its preparation method. By mass percentage, it includes the following components: 0.3–0.7% active caffeine, 5–10% moisturizer, 0.3–0.6% preservative, 15–25% skin-revitalizing ingredient, 0.05–0.5% bisabolol, 0.2–0.6% stabilizer, 2–4% potassium azeloyl diglycinate, and 0.05–0.3% vitamin E, with the balance being deionized water. This solution exhibits excellent moisturizing and nourishing effects, repairs damaged skin, improves skin firmness, and provides anti-aging repair, but it is relatively weak in addressing the cells' intrinsic "self-repair ability."

[0004] In view of this, the present invention is hereby proposed. Summary of the Invention

[0005] The problem solved by this invention is that most existing serums enhance skin metabolism through exogenous active ingredients, but have a weak ability to "self-repair" cells.

[0006] To address the aforementioned issues, this invention provides a skincare essence composed of 80-120 mL of a nanoemulsion system containing α-bisabolol and 4-6 mL of a liposome dispersion containing rapamycin.

[0007] Preferably, the nanoemulsion system containing α-bibasol is composed of the following components: 1.0-3.0g α-bibasol, 3.0-4.0g squalane, 3.0-8.0g caprylic / capric triglyceride, 2.0-4.0g lecithin, 1.0-3.0g PEG-40 hydrogenated castor oil, 0.1-0.5g β-glucan, 0.2-2.0g sodium hyaluronate, 7-15g glycerin, 0.5-2.0g tocopheryl acetate, 0.4-0.8g preservative, and 150-180mL buffer solution.

[0008] Preferably, the preservative is composed of phenoxyethanol and ethylhexylglycerin in a mass ratio of 5-10:1-3.

[0009] Preferably, the liposome dispersion containing rapamycin is composed of the following components: 2.0-6.0g soybean lecithin, 0.5-3.0g cholesterol, 0.2-0.5g rapamycin, 1.5-4.5g trehalose, and 50-70mL PBS buffer.

[0010] Preferably, the mass ratio of soybean lecithin, cholesterol, and rapamycin is 9-11:1.8-2:0.9-1.1.

[0011] Preferably, the preparation method includes: slowly adding a predetermined amount of rapamycin liposome dispersion to the α-bisamol nanoemulsion system, stirring at 150-300 rpm for 6-10 min, and adjusting the pH to 5.8-6.0 with citrate-phosphate buffer to obtain the final product.

[0012] Preferably, the α-bisabolol nanoemulsion system is prepared by the following method:

[0013] S1. Weigh out squalane and caprylic / capric triglycerides according to the specified amounts, mix them well, and heat them to a constant temperature in a water bath at 45-50℃; add tocopheryl acetate and stir slowly until completely dissolved; add α-bisabolol and continue stirring until the system forms a clear, homogeneous, and transparent oil phase; add lecithin and continue stirring until completely dissolved to obtain a lipophilic oil phase;

[0014] S2. Prepare a citrate-phosphate buffer solution with a pH of 5.9±0.1. Add glycerol and stir to dissolve. Add β-glucan and stir at 800-1200 rpm for 5-15 min at room temperature to pre-swell. Add sodium hyaluronate and stir at 500-800 rpm for 15-30 min until no visible particles are visible. Add 0.60 g of preservative and 2.0 g of PEG-40 hydrogenated castor oil at 35°C. Stir at 500-800 rpm for 10-15 min until completely dissolved to obtain an aqueous matrix.

[0015] S3. The lipophilic oil phase is added dropwise to the aqueous matrix and pre-emulsified by stirring at 500-800 rpm for 3-8 min. Then, it is transferred to a high-shear homogenizer and sheared at 6000-12000 rpm for 3-10 min. After cooling to room temperature, a nanoemulsion system with an average particle size of 80-150 nm is obtained.

[0016] Preferably, the rapamycin liposome dispersion is prepared by the following method: 50-70 mL of PBS buffer is heated to 36-40 °C and kept warm for later use; soybean lecithin, cholesterol, and rapamycin are dissolved in 20-40 mL of anhydrous ethanol and stirred at room temperature until clear. Then, the ethanol is slowly added dropwise to the stirred PBS buffer and rotary evaporated under reduced pressure until there is no obvious ethanol odor in the system, thus obtaining a crude rapamycin liposome dispersion; trehalose is added to the crude dispersion to achieve a final concentration of 3-5 wt%, and stirred until completely dissolved, thus obtaining the final product.

[0017] Preferably, the water bath temperature for the reduced pressure rotary evaporator is 46-50℃, and the system pressure is 150-300mbar.

[0018] Compared with the prior art, the skin care essence and preparation method described in the embodiments of the present invention have the following beneficial effects: 1) The present invention is the first to use rapamycin and α-bisabolol in combination. The liposomes containing rapamycin and the nano-emulsion droplets containing α-bisabolol are distributed in the stratum corneum-epidermal microenvironment within a similar particle size range. The synergistic effect of the two can not only inhibit local inflammatory response and reduce irritation, but also improve intracellular autophagy and repair capabilities; 2) Rapamycin is located in the liposome bilayer structure to improve its stability. At the same time, it regulates autophagy and intracellular homeostasis through the mTOR pathway to achieve deep repair and anti-aging effects on skin cells; 3) α-bisabolol is uniformly encapsulated in the nanoemulsion system. Under the synergistic effect of squalane and caprylic / capric triglycerides, it is easier to penetrate into the lipid channels of the stratum corneum, quickly relieve skin discomfort caused by exogenous stimulation and inflammatory factors, and reduce the irritation risk that active ingredients such as rapamycin may cause. Attached Figure Description

[0019] Figure 1 The effect of the skin care essence described in this invention on cell activity;

[0020] Figure 2 The results of human sensitization of the skin care essence described in this invention;

[0021] Figure 3 This is the result of the inhibitory effect of the skin care essence described in this invention on inflammatory factors;

[0022] Figure 4 This invention relates to the effect of the skincare essence on autophagy. Detailed Implementation

[0023] To make the above-mentioned objects, features, and advantages of the present invention more apparent and understandable, specific embodiments of the present invention will be described in detail below with reference to the accompanying drawings. Without conflict, the technical features of the embodiments of the present invention can be combined with each other.

[0024] As we age, wrinkles, sagging, and other aging-related skin problems gradually appear, attracting increasing attention from beauty enthusiasts in modern society. Research shows that one of the key causes of skin aging and damage is the decline in skin cell function and the accumulation of metabolic waste. Activating autophagy can promote skin cell renewal and repair, improving cell damage caused by aging and inflammation. Therefore, skincare strategies centered on autophagy are considered a gentler, more precise, and long-lasting new direction in beauty. Furthermore, chronic inflammation leads to collagen degradation, melanin deposition, and impaired skin barrier function. Therefore, anti-inflammatory measures are another key to maintaining skin homeostasis, delaying aging, and improving skin texture.

[0025] Rapamycin, a secondary metabolite secreted by *Streptomyces spp.*, was first discovered in 1975 from the soil of Easter Island, Chile. It is commonly used as a novel immunosuppressant with good efficacy, low toxicity, and no nephrotoxicity. Further research has shown that topical application of creams containing rapamycin can reduce wrinkles and sagging, improve skin tone, improve collagen expression, and inhibit P16 protein expression. However, its long onset of action hinders clinical application and market commercialization. α-Bisabolol, a natural sesquiterpene alcohol, exerts significant anti-inflammatory, antioxidant, antibacterial, and sedative effects by inhibiting the NF-κB and COX-2 pathways. Primarily found in chamomile and Brazilian cartiera, it is favored by skincare professionals, especially those with sensitive skin, due to its good biocompatibility and safety. However, as a highly lipophilic small molecule, it is prone to local accumulation and crystal precipitation under conventional emulsification conditions, leading to unsatisfactory efficacy in final serums and other skincare products. Therefore, the applicant proposes the following technical solution:

[0026] Example 1

[0027] A skincare essence comprising 100 mL of α-biazinool nanoemulsion system and 5.2 mL of rapamycin liposome dispersion is prepared by the following method: a predetermined amount of rapamycin liposome dispersion is slowly added to the α-biazinool nanoemulsion system, stirred at 300 rpm for 6 min, and the pH is adjusted to 5.8 with citrate-phosphate buffer.

[0028] The α-bisabolol nanoemulsion system described herein is composed of the following components:

[0029] Components Mass (g) α-Bisabolol 2.0 squalane 4.0 Caprylic / Capric Triglycerides 6.0 Lecithin 3.0 PEG-40 hydrogenated castor oil 2.0 β-glucan 0.30 Sodium hyaluronate 0.50 glycerin 8.0 Tocopheryl acetate 1.0 preservative 0.60 Buffer solution 170mL

[0030] Prepared using the following method:

[0031] S1, Preparation of lipophilic oil phase

[0032] Weigh 4g of squalane and 6g of caprylic / capric triglycerides, mix well, and keep the temperature constant at 45℃ in a water bath; add 1.0g of tocopheryl acetate and stir slowly until completely dissolved; add 2.0g of α-bisabolol and continue stirring until the system forms a clear, homogeneous, transparent oil phase; add 3.0g of lecithin and continue stirring at 45℃ until completely dissolved to obtain a lipophilic oil phase;

[0033] S2, Preparation of aqueous matrix

[0034] Prepare a citrate-phosphate buffer solution with pH 5.9 ± 0.1. Add 8.0 g of glycerol and stir to dissolve. Add 0.30 g of β-glucan and stir at 1000 rpm for 10 min at room temperature for pre-swelling. Add 0.50 g of sodium hyaluronate and stir at 600 rpm for 20 min at room temperature until no visible particles are visible. Add 0.60 g of preservative and add 2.0 g of PEG-40 hydrogenated castor oil at 35°C. Stir at 600 rpm for 15 min until completely dissolved to obtain an aqueous matrix. The preservative consists of 0.48 g of phenoxyethanol and 0.12 g of ethylhexylglycerin.

[0035] S3, Nanoemulsion

[0036] The lipophilic oil phase at 45℃ was slowly added to the aqueous matrix at 36℃ at a rate of 1 drop / second, and pre-emulsification was completed by stirring at 600 rpm. The mixture was then transferred to a high-shear homogenizer and sheared at 8000 rpm for 5 min. After cooling to room temperature, a nanoemulsion system with an average particle size of 80-150 nm was obtained.

[0037] The rapamycin liposome dispersion is composed of the following components:

[0038] Components mass or volume Soy lecithin 4.0g cholesterol 0.8g Rapamycin 0.4g PBS buffer 60 mL Trehalose 2.8g

[0039] Prepared using the following method:

[0040] Heat 60 mL of PBS buffer (pH 7.3 ± 0.1) to 38 °C and keep warm for later use. Weigh 4.0 g of soybean lecithin, 0.8 g of cholesterol, and 0.4 g of rapamycin and dissolve them in 30 mL of anhydrous ethanol. Stir at room temperature until clear, then slowly add the solution dropwise to the stirred PBS buffer. Transfer the solution to a rotary evaporator and evaporate under reduced pressure until there is no obvious ethanol odor, to obtain a crude dispersion of rapamycin liposomes. The operating parameters are: water bath temperature 48 °C and system pressure 220 mbar. Add a predetermined amount of trehalose to the crude dispersion to achieve a final concentration of 4 wt%, and stir gently until the trehalose is completely dissolved.

[0041] Example 2

[0042] A skincare essence comprising 120 mL of α-biazinool nanoemulsion system and 4 mL of rapamycin liposome dispersion is prepared by the following method: a predetermined amount of rapamycin liposome dispersion is slowly added to the α-biazinool nanoemulsion system, stirred at 150 rpm for 10 min, and the pH is adjusted to 6.0 with citrate-phosphate buffer.

[0043] The α-bisabolol nanoemulsion system described herein is composed of the following components:

[0044] Components Mass (g) α-Bisabolol 1.0 squalane 3.0 Caprylic / Capric Triglycerides 8.0 Lecithin 2.0 PEG-40 hydrogenated castor oil 1.0 β-glucan 0.1 Sodium hyaluronate 2.0 glycerin 7.0 Tocopheryl acetate 0.5 preservative 0.4 Buffer solution 150mL

[0045] Prepared using the following method:

[0046] S1, Preparation of lipophilic oil phase

[0047] Squalane and caprylic / capric triglycerides were mixed and kept at a constant temperature of 50°C in a water bath. Tocopheryl acetate was added and stirred slowly until completely dissolved. α-Bisabolol was added and stirring was continued until the system formed a clear, homogeneous, and transparent oil phase. Lecithin was added and stirred continuously at 50°C until completely dissolved to obtain a lipophilic oil phase.

[0048] S2, Preparation of aqueous matrix

[0049] Prepare a pH 6.0 citrate-phosphate buffer solution by adding glycerol and stirring to dissolve it, then add β-glucan and stir at 1200 rpm for 5 min at room temperature for pre-swelling; add sodium hyaluronate and stir at 500 rpm for 30 min at room temperature until no visible particles are visible; after adding the preservative, add PEG-40 hydrogenated castor oil at 40°C and stir at 800 rpm for 10 min until completely dissolved to obtain an aqueous matrix, wherein the preservative is composed of phenoxyethanol and ethylhexylglycerin in a mass ratio of 5:1.

[0050] S3, Nanoemulsion

[0051] The lipophilic oil phase at 50°C was slowly dripped into the aqueous matrix at 40°C, and pre-emulsification was completed by stirring at 800 rpm. The mixture was then transferred to a high-shear homogenizer and sheared at 12,000 rpm for 3 minutes. After cooling to room temperature, a nanoemulsion system with an average particle size of 80-150 nm was obtained.

[0052] The rapamycin liposome dispersion is composed of the following components:

[0053] Components mass or volume Soy lecithin 2.0g cholesterol 0.5g Rapamycin 0.2g PBS buffer 50 mL Trehalose 1.5g

[0054] Prepared using the following method:

[0055] Heat PBS buffer (pH 7.3 ± 0.1) to 38°C and keep warm for later use. Dissolve soybean lecithin, cholesterol, and rapamycin in anhydrous ethanol and stir at room temperature until clear. Then, slowly add the solution dropwise to the stirred PBS buffer. Transfer the solution to a rotary evaporator and evaporate under reduced pressure until there is no obvious ethanol odor, to obtain a crude dispersion of rapamycin liposomes. The operating parameters are: water bath temperature 50°C and system pressure 300 mbar. Add a predetermined amount of trehalose to the crude dispersion to achieve a final concentration of 3 wt%, and stir gently until the trehalose is completely dissolved.

[0056] Example 3

[0057] A skincare essence comprising 80 mL of α-biazinool nanoemulsion system and 6 mL of rapamycin liposome dispersion is prepared by the following method: a predetermined amount of rapamycin liposome dispersion is slowly added to the α-biazinool nanoemulsion system, stirred at 300 rpm for 6 min, and the pH is adjusted to 5.8 with citrate-phosphate buffer.

[0058] The α-bisabolol nanoemulsion system described herein is composed of the following components:

[0059] Components Mass (g) α-Bisabolol 3.0 squalane 3.5 Caprylic / Capric Triglycerides 8.0 Lecithin 4.0 PEG-40 hydrogenated castor oil 3.0 β-glucan 0.5 Sodium hyaluronate 2.0 glycerin 15.0 Tocopheryl acetate 2.0 preservative 0.8 Buffer solution 180mL

[0060] Prepared using the following method:

[0061] S1, Preparation of lipophilic oil phase

[0062] Weigh out squalane and caprylic / capric triglycerides, mix them well, and keep the temperature in a water bath at 45°C; add tocopheryl acetate and stir slowly until completely dissolved; add α-bisabolol and continue stirring until the system forms a clear, homogeneous, transparent oil phase; add lecithin and continue stirring at 45°C until completely dissolved to obtain a lipophilic oil phase;

[0063] S2, Preparation of aqueous matrix

[0064] Prepare a citrate-phosphate buffer solution with pH 5.8. Add glycerol and stir to dissolve. Add 0.30 g of β-glucan and stir at 800 rpm for 15 min at room temperature for pre-swelling. Add sodium hyaluronate and stir at 800 rpm for 15 min at room temperature until no visible particles are visible. After adding the preservative, add PEG-40 hydrogenated castor oil at 35°C and stir at 800 rpm for 30 min until completely dissolved to obtain an aqueous matrix. The preservative is composed of phenoxyethanol and ethylhexylglycerin in a mass ratio of 1:1.

[0065] S3, Nanoemulsion

[0066] The lipophilic oil phase at 45℃ was added dropwise to the aqueous matrix at 36℃, and the mixture was stirred at 800 rpm for 5 min to complete the pre-emulsification. The mixture was then transferred to a high-shear homogenizer and sheared at 8000 rpm for 10 min. After cooling to room temperature, a nanoemulsion system with an average particle size of 80-150 nm was obtained.

[0067] The rapamycin liposome dispersion is composed of the following components:

[0068] Components mass or volume Soy lecithin 6.0g cholesterol 3.0g Rapamycin 0.2g PBS buffer 70 mL Trehalose 4.5g

[0069] Prepared using the following method:

[0070] Heat PBS buffer (pH 7.4) to 38°C and keep warm for later use. Dissolve soybean lecithin, cholesterol, and rapamycin in anhydrous ethanol and stir at room temperature until clear. Then, slowly add the solution to the stirred PBS buffer. Transfer the solution to a rotary evaporator and evaporate under reduced pressure until there is no obvious ethanol odor, to obtain a crude dispersion of rapamycin liposomes. The operating parameters are: water bath temperature 46°C and system pressure 150 mbar. Add a predetermined amount of trehalose to the crude dispersion to achieve a final concentration of 4 wt%, and stir gently until the trehalose is completely dissolved.

[0071] Experimental Example 1: Cell Viability Detection

[0072] Human immortalized keratinocytes (HaCaT) were selected and cultured in DMEM basal medium supplemented with 10% fetal bovine serum for later use. HaCaT cells were seeded into 96-well plates at a density of 5 × 10³ cells / well and incubated at 37°C with 5% CO2 for about 12 hours until the cells adhered stably. The cells were then divided into a blank control group and experimental groups 1-3. The blank control group was given an equal volume of the carrier system without any essence components. Experimental groups 1-3 were given 0.01%, 0.1%, and 1% (v / v) equivalent concentrations of the skin care essence prepared in Example 1, respectively. All groups were incubated at 37°C with 5% CO2 for another 48 hours.

[0073] Then, an appropriate amount of CCK-8 reagent was added to each well, and the cells were incubated again under the same culture conditions for 2 hours. The absorbance of each well was measured at 450 nm using a microplate reader. With the cell viability of the blank control group as 100% as the baseline, the relative cell viability of each concentration treatment group of the essence was calculated. The results are shown in […]. Figure 1 .

[0074] CCK-8 reagent is a commonly used tool for detecting cell viability. Its principle is that water-soluble tetrazolium salt can only be reduced to orange-yellow formazan by dehydrogenases in living cells, and the amount of formazan produced is positively correlated with the number of living cells and cell viability—the more living cells and the higher their activity, the more formazan is produced, and the higher the absorbance value at 450nm detected by the microplate reader. Figure 1 It can be seen that different concentrations of serum do not affect the concentration of CCK-8, indicating that the serum does not affect the cell activity of keratinocytes.

[0075] Experimental Example 2: Human-derived sensitization

[0076] Human acute monocytic leukemia cell line THP-1 was selected and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C and 5% CO2. THP-1 cells were then cultured at a rate of 1-2 × 10⁻⁶ cells / year. 5 Cells were seeded at a density of 1 / mL into 6-well plates and cultured for about 12 hours until the cells were stable. The cells were then divided into a blank control group and experimental groups 1-3. The blank control group was given an equal volume of carrier system without the active ingredients of the essence. The experimental groups 1-3 were given 0.01%, 0.1%, and 1% (v / v) equivalent concentrations of the skin care essence prepared in Example 1, respectively. All groups were incubated at 37°C and 5% CO2 for 48 hours.

[0077] THP-1 cells were collected from each well and washed with PBS (phosphate-buffered saline). The washed cells were then aliquoted according to standard procedures and stained with CD86-FITC and CD54-PE fluorescent antibodies, respectively. The fluorescence intensity of CD86 and CD54 molecules on the cell surface was detected by flow cytometry. The fluorescence intensity changes of experimental groups 1-3 were compared with those of the blank control group. The results are shown in [Figure number missing]. Figure 2 .

[0078] Depend on Figure 2 It can be seen that different concentrations of the serum did not significantly change the fluorescence intensity of CD86 and CD54 molecules on the surface of THP-1 cells, indicating that the serum did not cause any risk of allergies.

[0079] Experiment Example 3: Inhibition of inflammatory factors

[0080] This experiment used HaCaT cells to evaluate the regulatory effects of the serum on the release of inflammatory mediators and the NF-κB signaling pathway. Specifically, human immortalized keratinocytes (HaCaT) were cultured in DMEM basal medium supplemented with 10% fetal bovine serum. HaCaT cells were seeded at a density of 5 × 10³ cells / well into 96-well plates and incubated at 37°C with 5% CO2 for approximately 12 hours until the cells were stably adhered. The cells were then divided into a blank control group and experimental groups 1-3. The blank control group received an equal volume of the carrier system without the serum. Experimental groups 1-3 received 0.01%, 0.1%, and 1% (v / v) equivalent concentrations of the skincare serum prepared in Example 1, respectively, based on the effective ingredient content. Subsequently, inflammatory stimulation was administered: IL-1β (10... In combination with TNF-α (10 ng / mL) or LPS (1 μg / mL), the cells were incubated for another 24 hours. After incubation, the cell culture supernatant was collected, and the levels of IL-6 and IL-8 were detected by ELISA. The results are shown below. Figure 3 .

[0081] Depend on Figure 3 It is known that different concentrations of serum can inhibit the secretion of IL-6 and IL-8 by HaCaT cells, especially the addition of serum at a concentration of 0.1% or higher has a significant inhibitory effect on inflammation.

[0082] Experimental Example 4: Autophagy

[0083] Autophagy involves many key enzymes, among which ATG5, as a core regulatory protein, maintains cellular homeostasis through the classic autophagy pathway. This experiment used HaCaT to evaluate the regulatory effect of the serum on autophagy.

[0084] Specifically, immortalized human keratinocytes (HaCaT) were selected and cultured in DMEM basal medium supplemented with 10% fetal bovine serum for later use. HaCaT cells were seeded into 96-well plates at a density of 5 × 10³ cells / well and incubated at 37°C with 5% CO2 for about 12 hours until the cells adhered stably. The cells were then divided into a blank control group and experimental groups 1-3. The blank control group was given an equal volume of carrier system without any essence components. Experimental groups 1-3 were given 0.01%, 0.1%, and 1% (v / v) equivalent concentrations of the skin care essence prepared in Example 1, respectively, based on the effective ingredient concentration. After incubation, the cell culture supernatant was collected, and the activity and content of ATG5 were detected by ELISA.

[0085] Depend on Figure 4 It is known that different concentrations of the essence can enhance the activity of ATG5 in HaCaT cells, especially the addition of more than 0.1% of the essence has a significant effect on enhancing autophagy.

[0086] While the present invention has been disclosed above, it is not limited thereto. Any person skilled in the art can make various modifications and alterations without departing from the spirit and scope of the invention; therefore, the scope of protection of the present invention should be determined by the scope defined in the claims.

Claims

1. A skin care serum, characterized by, The α-bisabolol-containing nanoemulsion system is composed of 80-120 mL of α-bisabolol-containing nanoemulsion system and 4-6 mL of rapamycin-containing liposome dispersion.

2. The skin care serum of claim 1, wherein, The α-bisabolol-containing nanoemulsion system is composed of 80-120 mL of α-bisabolol-containing nanoemulsion system and 4-6 mL of rapamycin-containing liposome dispersion.

3. The skin care serum of claim 2, wherein, The α-bisabolol-containing nanoemulsion system is composed of 80-120 mL of α-bisabolol-containing nanoemulsion system and 4-6 mL of rapamycin-containing liposome dispersion.

4. The skin care serum of claim 1, wherein, The preservative is composed of phenoxyethanol and ethylhexylglycerin in a mass ratio of 5-10:1-3.

5. The skin care serum of claim 4, wherein, The rapamycin-containing liposome dispersion is composed of 2.0-6.0 g of soy lecithin, 0.5-3.0 g of cholesterol, 0.2-0.5 g of rapamycin, 1.5-4.5 g of trehalose, and 50-70 mL of PBS buffer.

6. The method of preparing the skin care serum according to any one of claims 1 to 5, characterized in that: The mass ratio of the soy lecithin, cholesterol, and rapamycin is 9-11:1.8-2:0.9-1.

1.

7. The method of claim 6, wherein the skin essence is prepared by the steps of: The preparation method comprises slowly adding a predetermined amount of rapamycin liposome dispersion to the α-bisabolol nanoemulsion system, stirring at 150-300 rpm for 6-10 min, and adjusting the pH to 5.8-6.0 with citrate-phosphate buffer to obtain the product. The α-bisabolol nanoemulsion system is prepared by the following method: S1. Weigh the squalane and caprylic / capric triglyceride according to the amount, mix well, and heat to constant temperature in a 45-50°C water bath; add tocopherol acetate and slowly stir until completely dissolved; Add α-bisabolol and continue stirring until the system is a clear and uniform transparent oil phase; add lecithin and continue stirring until completely dissolved to obtain a lipophilic oil phase; S2. Prepare a citrate-phosphate buffer with a pH of 5.9±0.1, add glycerol and stir to dissolve, add β-glucan, and pre-swelling at room temperature at 800-1200 rpm for 5-15 min; add sodium hyaluronate and stir at 500-800 rpm for 15-30 min until no visible particles are present; add 0.60 g of preservative and 2.0 g of PEG-40 hydrogenated castor oil at 35°C, and stir at 500-800 rpm for 10-15 min until completely dissolved to obtain the water phase matrix; S3. Add the lipophilic oil phase dropwise to the water phase matrix and stir at 500-800 rpm for 3-8 min for pre-emulsification; then transfer to a high-shear homogenizer and shear at 6000-12000 rpm for 3-10 min, and cool to room temperature to obtain a nanoemulsion system with an average particle size of 80-150 nm.

8. The skin care serum of claim 6, wherein, The rapamycin liposome dispersion is prepared by the following method: heating 50-70 mL of PBS buffer to 36-40℃ and keeping warm; dissolving soybean lecithin, cholesterol and rapamycin in 20-40 mL of anhydrous ethanol, stirring at room temperature until clear, then slowly adding to the stirring PBS buffer, and rotary evaporating under reduced pressure until no obvious ethanol odor is left in the system to obtain a crude rapamycin liposome dispersion; adding trehalose to the crude dispersion to a final concentration of 3-5 wt%, and stirring until completely dissolved.

9. The skin care serum of claim 8, wherein, The water bath temperature for the rotary evaporation under reduced pressure is 46-50℃, and the system pressure is 150-300 mbar.

Images